LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Charles River Laboratories International Inc

Gesloten

SectorGezondheidszorg

137.74 -2.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

140.91

Max

142.26

Belangrijke statistieken

By Trading Economics

Inkomsten

240M

26M

Verkoop

-18M

984M

K/W

Sectorgemiddelde

592.3

56.602

EPS

2.34

Winstmarge

2.629

Werknemers

18,700

EBITDA

271M

184M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+12.74% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-849M

7B

Vorige openingsprijs

140.05

Vorige sluitingsprijs

137.74

Nieuwssentiment

By Acuity

50%

50%

160 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 aug 2024, 10:30 UTC

Top Nieuws

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Charles River Laboratories International Inc Prognose

Koersdoel

By TipRanks

12.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 158.93 USD  12.74%

Hoogste 188 USD

Laagste 100 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Charles River Laboratories International Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

15 ratings

3

Buy

12

Hold

0

Sell

Technische score

By Trading Central

117.16 / 144.77Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

160 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.